Раздел 3.4

  1. Haas R., Bonvalot S., Miceli R., et al. Radiotherapy for retroperitoneal liposarcoma: a report from the Transatlantic Retroperitoneal Sarcoma Working Group. Cancer, 2019, April 15, 1290-1300 doi: 10.1002/cncr.31927.
  2. Giuliano K., Nagarajan N., Canner J.K., Wolfgang C.L., Bivalacqua T., Terezakis S., Herman J., Schneider E.B., Ahuja N. Predictors of improved survival for patients with retroperitoneal sarcoma. Surgery. 2016 Dec;160(6):1628-1635. doi: 10.1016/j.surg.2016.05.04.
  3. Gronchi A., Strauss D.C., Miceli R., et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the Multi-institutional Collaborative RPS Working Group. Ann Surg. 2016;263:1002-1009.
  4. Brenneman R., Sharifai N., Fischer-Valuck B., Hassanzadeh C., Guzelian J., Chrisinger J., Michaiski J., Oppelt P., Baumann B. Abscopal effect following proton beam radiotherapy in a patient with inoperable metastatic petroperitoneal sarcoma. Front. Oncol., 2019, 9:922. doi: 10.3389/fonc.2019.00922.
  5. Lewis J.J., Leung D., Woodruff J.M., Brennan M.F. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998; 228: 355–65.
  6. Caudle A.S., Tepper J.E., Calvo B.F., et al. Complications associatedwith neoadjuvant radiotherapy in the multidisciplinary treatment of retroperitoneal sarcomas. Ann Surg Oncol 2007; 14: 577–82.
  7. Keung E.Z., Hornick J.L., Bertagnolli M.M., Baldini E.H., Raut C.P. Predictors of outcomes in patients with primary retroperitoneal dediff erentiated liposarcoma undergoing surgery. J Am Coll Surg 2014; 218: 206–17.
  8. Haas R., Miah A., LePechoux C., DeLaney T., Baldini E., Alektiar K., O’Sullivan B. Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies. Radiotherapy and Oncology, 2016, 119, 14–21. Doi:10.1016/j.radonc.2015.12.002
  9. Rhomberg W. The radiation response of sarcomas by histologic subtypes: a review with special emphasis given to results achieved with razoxane. Hindawi Publishing Corporation. Sarcoma. Volume 2006, Article ID 87367, Pages 1-9; doi 10.1155/SRCM/2006/87367.
  10. Lansu J., Bovèe J., Braam P., et al. Dose reduction of preoperative radiotherapy in myxoid liposarcoma: A nonrandomized controlled trial. JAMA Oncol 2021; 7:e205865.
  11. DeLaney T., Chen Y., Baldini E., Wang D., Adams J., Hickey S. , Yeap B. ,Hahn S., Bernstein K., Nielsen G., Choy E., Mullen J., Yoon S.. Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Advances in Radiaton Oncology 2017, 2, 85-93.
  12. Tames H. Suit H. Tumor radioresponsiveness versus fractionation sensitivity. Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):687-91. doi: 10.1016/0360-3016( 86)90081-7.
  13. Benzen S., Joiner M. The linear-quadratic approach in clinical practice in Basic Clinical Radiology. Edited by M.C. Joiner, A.J. Vender Kogel Taylor&Francis, 2019, Pages 112-124
  14. von Mehren M., Randall R., Benjamin R.,.et al, Soft Tissue Sarcoma, Version 2.2018 J Natl Compr Canc Netw 2018;16(5):536–563 doi: 10.6004/jnccn.2018.0025.
  15. Sampath S., Schultheiss T.E., Hitchcock Y.J., et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-institutional analysis of 821 patients. International journal of radiation oncology, biology, physics 2011;81:498-505.
  16. White, L.M.; Wunder, J.S.; Bell, R.S.; O‘Sullivan, B.; Catton, C.; Ferguson, P.; Blackstein, M.; Kandel, R.A. Histologic assessment of peritumoral edema in soft tissue sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61, 1439–1445.
  17. Simon, M.A., Enneking, W.F. The management of soft-tissue sarcomas of the extremities J Bone Joint Surg Am. 1976; 58:317-327.
  18. Enneking, W.F. ∙ Spanier, S.S. ∙ Malawer, M.M. The effect of the anatomic setting on the results of surgical procedures for soft parts sarcoma of the thigh Cancer. 1981; 47:1005-1022
  19. Schwartz D.L., Einck J., Bellon J., Laramore G.E. Fast neutron radiotherapy for soft tissue and cartilaginous sarcomas at high risk for local recurrence.Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):449-56.
  20. Haas R.L., Delaney T.F., O'Sullivan B., et al. Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where? Int J Radiat Oncol Biol Phys 2012;84:572-580.
  21. Albertsmeier M., Rauch A., Roeder F., et al. External Beam RadiationTherapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2018;25:754-767.
  22. O’Sullivan B., Davis A.M., Turcotte R., et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002; 359:2235–2241.
  23. Gingrich A.A., Bateni S.B., Monjazeb A.M., et al. Neoadjuvant Radiotherapy is Associated with R0 Resection and Improved Survival for Patients with Extremity Soft Tissue Sarcoma Undergoing Surgery: A National Cancer Database Analysis. Ann Surg Oncol 2017;24:3252–3263.
  24. O’Sullivan B., Davis A.M., Turcotte R., et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359:2235–2241.
  25. O’Sullivan B., Davis A., Turcotte R., et al. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma [abstract]. J Clin Oncol 2004;22(14_Suppl):Abstract 9007.
  26. Davis A.M., O’Sullivan B., Turcotte R., et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 2005;75:48–53.
  27. Yang J.C.., Chang AE., Baker A.R., et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197–203.
  28. Beane J.D., Yang J.C., White D., et al. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann Surg Oncol 2014;21:2484–2489.
  29. Cassier P.A., Kantor G., Bonvalot S., et al. Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study. Ann Oncol 2014;25:1854–1860.
  30. Trieu D., Gong H., Benoit D., Choong P.F.M. Radiotherapy versus limb-sparing surgery alone in low-grade soft-tissue sarcoma of the extremity and trunk wall: a systematic review and meta-analysis ANZ J Surg. 2024 Apr;94(4):566-571. doi: 10.1111/ans.18858
  31. Delaney T.F., Kepka L., Goldberg S.I., et al. RT therapy for control of soft tissue sarcomas resected with positive margins. Int J Radiat Oncol Biol Phys 2007;67:1460-1469.
  32. Pisters P.W., Harrison L.B., Leung D.H., et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859–868.
  33. Alektiar K.M., Leung D., Zelefsky M.J., et al. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. Ann Surg Oncol 2002;9:48–56.
  34. Jonston Р. А., Sindelar W. F., Кinsella Т. J. // Сurr. Ргоbl. Саnсеr. 1994. Vоl. 18, № 5. Р. 249-290.
  35. Azinovic I., Monge R.M, Aristu J.J. et al. Intraoperative radiotherapy electron boost followed by moderate doses of external beam radiotherapy in resected soft-tissue sarcoma of the extremities. //Radiother Oncol. 2003. Jun;67(3):331-337.
  36. Roeder F., Lehner B., Schmitt T. et al. Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial. BMC Cancer 2014; 14:350. DOI: 10.1186/1471-2407-14-350.
  37. Зубарев А.Л., Курильчик А.А., Кудрявцева Г.Т. и др. Интраоперационная лучевая терапия (ИОЛТ) в комбинированном лечении сарком опорно-двигательного аппарата // Онкохирургия. 2010. № 3. С. 19–25.
  38. Naghavi A.O., Fernandez D.C., Mesko N., et al. American Brachytherapy Society consensus statement for soft tissue sarcoma brachytherapy. Brachytherapy 2017;16:466-489.
  39. Pohar S., Haq R., Liu L., et al. Adjuvant high-dose-rate and low-doserate brachytherapy with external beam radiation in soft tissue sarcoma: a comparison of outcomes. Brachytherapy 2007;6:53-57.
  40. Alektiar K.M., Brennan M.F., Healey J.H., Singer S. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol 2008;26:3440–3444.
  41. O’Sullivan B., Griffin A.M., Dickie C.I., et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer 2013;119:1878–1884.
  42. Alektiar K.M., Brennan M.F., Singer S. Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity. Cancer 2011;117:3229–3234.
  43. Blitzer G.C., Yadav P., Morris Z.S. The role of MRI guided Radiotherapy for soft tissue sarcomas. J Clin Med. 2022 Feb 17;11(4):1042. doi: 10.3390/jcm11041042.
  44. Roohani S., Ehret F., Kobus M.,  Flörcken A., Märdian S., Striefler J.K., Rau D., Öllinger R.,  Jarosch A., Budach V., Kaul D. Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review. Radiat Oncol. 2022 Sep 14;17(1):159. doi: 10.1186/s13014-022-02072-9.
  45. Bryant J.M., Mills M.N., Yang G.Q., Liveringhouse C., Palm R., Johnstone P.A., Miller J.T., Latifi K., Feygelman V., Naghavi A.O. Novel Definitive Hypofractionated Accelerated Radiation Dose-painting (HARD) for Unresected Soft Tissue Sarcomas Adv Radiat Oncol. 2024 Jan 24;9(4):101447. doi: 10.1016/j.adro.2024.101447.
  46. Tepper J.E., H D Suit H.D. Radiation therapy alone for sarcoma of soft tissue. Cancer 1985 Aug 1;56(3):475-9. doi: 10.1002/1097-0142.
  47. Kepka L., Delaney T.F., Suit H.D., et al. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2005;63:852-859.
  48. Mizoe J.E., Hasegawa A., Takagi R., Bessho H., Onda T. and Tsujii H.: Carbon-ion radiotherapy for skull base chordoma. Skull Base19(3): 219-224, 2009. PMID: 19881902. DOI: 10.1055/s-0028-1114295.
  49. Schulz-Ertner D., Nikoghosyan A., Hof H., Didinger B., Combs S.E., Jakel O., Karger C.P., Edler L. and Debus J.: Carbon-ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol Biol Phys 67(1): 171-177, 2007. PMID: 17056193. DOI:10.1016/j.ijrobp.2006.08.027.
  50. Uhl M., Welzel T., Oelmann J., Habl G., Hauswald H., Jensen A., Ellerbrock M., Debus J. and Herfarth K.: Active raster scanning with carbon-ions: Reirradiation in patients with recurrent skull base chordomas and chondrosarcomas. Strahlenther Onkol 190(7): 686-691, 2014. PMID: 24663287. DOI: 10.1007/s00066-014-0608-2.
  51. Noel G., Feuvret L., Dhermain F., et al. Chordomas of the base of the skull and upper cervical spine. 100 patients irradiated by a 3D conformal technique combining photon and proton beams. Cancer Radiother. 2005;9(3):161-174.
  52. Weber D.C., Malyapa R., Albertini F., et al. Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiother Oncol. 2016;120(1):169-174.
  53. Kano H., Iqbal F.O., Sheehan J., Mathieu D., Seymour Z.A., Niranjan A., Flickinger J.C., Kondziolka D., Pollock B.E., Rosseau G., Sneed P.K., McDermott M.W., Lunsford L.D. Stereotactic radiosurgery for chordoma: a report from the North American Gamma Knife Consortium Neurosurgery. 2011 Feb;68(2):379-89. doi: 10.1227/NEU.0b013e3181ffa12c.PMID: 21135744.
  54. Mercado C.E., Holtzman A.L., Rotondo R., Rutenberg M.S., Mendenhall W.M. Proton therapy for skull base tumors: A review of clinical outcomes for chordomas and chondrosarcomas. Head Neck. 2019 Feb;41(2):536-541. doi: 10.1002/hed.25479.
  55. Goetz G., Mitic M., Mittermayr T., Wild C. Health technology assessment of Carbon-ion beam radiotherapy: a systematic review of clinical effectiveness and safety for 54 ncological indications in 12 tumour regions. Anticancer Res. 2019 Apr;39(4):1635-1650. doi: 10.21873/anticanres.13269.
  56. Kubota H., Demizu Y., Iwashita K. et.al. Definitive particle therapy using protons or carbon ions for dedifferentiated liposarcoma/ Clin Transl Radiat Oncol. 2024 Sep 22:49:100864 doi: 10.1016/j.ctro.2024.100864.
  57. Fiore M.R., Chalaszczyk A., Barcellini A. et.al. ClinicalOutcomesofCarbonIonRadiationTherapyforMalignantPeripheralNerveSheathTumors. Advances inRadiationOncology(2024) 9, 101619 doi.org/10.1016/j.adro.2024.101619.
  58. Nussbaum D., Rushing C., O Lane W., Cardona D., Kirsch D., Peterson B., Blazer D. Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. Lancet Oncol 2016; 17: 966–75 doi:10.1016/S1470-2045(16)30050-X.
  59. Chouliaras K., Senehi R., Ethun C., Poultsides G., Grignol V., Clarke C., Roggin K., Fields R, Schwartz P., Ronnekleiv-Ketly S., Ralph D'Agostino Jr., Johnson E., Levine E., Cardona K, Votanopoulos K. Role of radiation therapy for retroperitoneal sarcomas: An eight-institution study from the US Sarcoma Collaborative. J Sure Oncol. 2019 December; 120(7) :1227-123. dog:10.1002/jso.25694.
  60. Tseng W., Martinez S.,Do Ly., Tamurian R., Borys D., Canter R. Lack of survival benefit following adjuvant radiation in patients with retroperitoneal sarcoma: A SEER analysis. Journal of Surgical Research, 2011, 168, e173–e180 (2011) doi:10.1016/j.jss.2011.02.004.
  61. Trovik L., Ovrebo K., Almquist M., Haugland H., Rissler P., Eide J., EngeHau J., Monge O., Nyhus A.,. Elde I., Jebsen N. Adjuvant radiotherapy in retroperitoneal sarcomas. A Scandinavian Sarcoma Group study of 97 patients. Acta Oncologica, 2014, 53:9, 1165-1172. doi: 10.3109/0284186X.2014.921723
  62. Turner B., L. Hampton, D. Schiller, L.A. Mack, C. Robertson-More, H. Li, M.L. Quan, A. Bouchard-Fortier. Neoadjuvant radiotherapy followed by surgery compared with surgery alone in the treatment of retroperitoneal sarcoma: a population-based comparison. Curr Oncol. 2019 December;26(6):e766-e772
  63. Kim H., Koom W., Cho J., Kim H., Suh C. Efficacy of postoperative radiotherapy using modern techniques in patients with retroperitoneal soft tissue sarcoma. Yonsei Med J 2018 Nov;59(9):1049-1056, doi.org/10.3349/ymj.2018.59.9.1049.
  64. Cosper P., Olsen J., DeWees T., Tine B., Hawkins W., J Michalski J., Zoberi I.. Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience. Cosper et al. Radiation Oncology 2017, 12:198 doi 10.1186/s13014-017-0920-y.
  65. Sindelar W.F., Kinsella T.J., Chen P.W., DeLaney T.F., Tepper J.E., Rosenberg S.A. et al. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. Arch Surg Chic. Ill 1960. 1993;128:402–10.
  66. Alektiar K.M., Hu K., Anderson L., Brennan M.F., Harrison L.B. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2000;47:157–63.
  67. Petersen I.A., Haddock M.G., Donohue J.H., Nagorney D.M., Grill J.P., Sargent D.J., et al. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2002;52:469–75.
  68. Baldini E., Abrams R., Bosch W., Roberge D, Haas R., Catton C., Indelicato D., Olsen J., Deville C., Chen Y., , Finkelstein S., DeLaney T., Wang D. Retroperitoneal sarcoma target volume and organ at risk contour delineation agreement among NRG sarcoma radiation jncologists. Int J Radiat Oncol Biol Phys. 2015 August 1; 92(5): 1053-1059. doi:10.1016/j.ijrobp.2015.04.039.
  69. Swanson E.L., Indelicato D.J., Louis D., et al. Comparison of three-dimensional (3D) conformal proton radiotherapy (RT), 3D conformal photon RT, and intensitymodulated RT for retroperitoneal and intra-abdominal sarcomas. Int J Radiat Oncol Biol Phys 2012;83:1549-1557.
  70. Kraybill W. G., Haris J. et al. Long-term results of a phase II study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514, Cancer 116 (2010): 4613-4621.
  71. Raval R. R.; Frassica D.; Thornton K. et al. Evaluating the Role of Interdigitated Neoadjuvant Chemotherapy and Radiation in the Management of High-Grade Soft-Tissue Sarcoma: The Johns Hopkins Experience. Am J Clin Oncol. Author manuscript; available in PMC 2017 April 01.
  72. Саркомы мягких тканей. Под ред. А.Д. Каприна, М.Д. Алиева, А.А. Феденко. 2024. 320 с. ISBN 978-5-6050655-2-4.
  73. Eilber C., Rosen G., Eckardt J. et al. Treatment-Induced Pathologic Necrosis: A Predictor of Local Recurrence and Survival in Patients Receiving Neoadjuvant Therapy for High Grade Extremity Soft Tissue Sarcomas. J. Clin. Oncol. 2001, v. 19.
  74. Fletcher Ch.D.M., Unni K.K., Mertens F. (eds.) World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Soft Tissue and Bone. – Lyon: IARS press, 2002. – P. 264-270.
  75. Kraybill W.G., Harris J., Spiro I.J. et al. Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514. J. Clin. Oncol. 2006, v. 24 (4), p. 619-625.
  76. McDermed D., Miller L.M., Peabody T.D. et al. Primary Tumor Necrosis Predicts Distant Control in Locally Advanced Soft Tissue Sarcomas Following Preoperative Concurrent Chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2010, v. 15, 76 (4), p. 1147-1153.
  77. Ryan C.W., Montag A.G., Hosenpud J.R. et al. Histologic Response of Dose-intense Chemotherapy With Preoperative Hypofractionated Radiotherapy for Patients With High-risk Soft Tissue Sarcomas. Cancer. 2008, v. 112 (11), p. 2432-2439.
  78. Bedi M., King D.M., Shivakoti M. et al. Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy. Radiation Oncology. 2013, v. 8, p. 60.
  79. Toma S., Canavese G., Grimaldi A. et al. Concomitant chemo-radiotherapy in the treatment of locally advanced and/ or metastatic soft tissue sarcomas: Experience of the National Cancer Institute of Genoa. Oncol. Rep. 2003, v. 10, p. 641-647.
  80. Pisters P.W.T., Patel S.R., Prieto V.G. et al. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J. Clin. Oncol. 2004, v. 22, p. 3375-3380.
  81. Cormier J.N., Patel S.R., Herzog C.E. et al. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. Cancer. 2001, v. 92, p. 1550-1555.
  82. Bonvalot S., Le Pechous C et al. First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas. Clin Cancer Res. 2017.
  83. Tseng W.W., Zhou Sh. et al. Phase I adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. Cancer. 2015 October 15; 121(20): 3659–3667.
  84. Haas R.L., Gelderblom H. et al. A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities. Acta Oncologica, 2015; 54: 1195.
  85. Canter R. J., Borys D. et al. Phase I Trial of Neoadjuvant Conformal Radiotherapy plus Sorafenib for Patients with Locally Advanced Soft Tissue Sarcoma of the Extremity. Ann Surg Oncol. 2014 May;21(5):1616-23.
  86. Зубарев А.Л., Курильчик А.А., Курпешев О.К. и др. Локальная гипертермия в комбинированном лечении местно-распространенных сарком мягких тканей // Сибирский онкологический журнал 2015;1(3):55–60
  87. Issels R.D., Lindner L.H., Verweij J., et al; European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group and the European Society for Hyperthermic Oncology. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncol. 2018;4(4):483-492.
  88. De Jong M.A., Oldenborg S., Bing Oei S., et al. Reirradiation and hyperthermia for radiation-associated sarcoma. Cancer. 2012; 118(1):180–187. doi: 10.1002/cncr.26252.
  89. Linthorst M., Van Geel A.N., Baartman E.A., et al. Re-irradiation and hyperthermia after surgery for recurrent breast cancer. Radiother Oncol. 2013;109(2):188–193. doi: 10.1016/j.radonc.2013.05.010.
  90. Spałek M.J., Borkowska A.M., Telejko M., et al. The feasibility study of hypofractionated radiotherapy with regional hyperthermia in soft tissue sarcomas. Cancers (Basel). 2021;13(6):1332. doi: 10. 3390/cancers13061332.
Veltsista P.D., Oberacker E., Ademaj A., Corradini S., Eckert F., Flörcken A., et al. Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review. Int. J. Hyperthermia. 2023;40 doi: 10.1080/02656736.2023.2236337.